Xlife Sciences AG

Xlife Sciences AG Announces the listing of FUSE-AI GmbH on the London Stock Exchange in the First Half of 2025

Xlife Sciences AG enables international co-investors to enter the stock and is planning a dual listing on the London Stock Exchange Group (LSEG)

Xlife Sciences AG: Successful First Half of 2024 with Strategic Progress and Solid Financial Figures

Xlife Sciences AG Completes Strategic Review Process by Q3 2024

Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX

Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness

Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH

Xlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation Report

Xlife Sciences AG Publishes 2023 Annual Report

Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland

Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City

VERAXA Biotech AG acquires Synimmune GmbH to expand cancer pipeline

Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases

Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases

Revolutionary AI Algorithm «Prostate.Carcinoma.ai» Achieves EU MDR Class IIa Registration

Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million

ESG Report shows status quo and outlines path for future sustainability improvements Media Release Zurich, September 29, 2023

Xlife Sciences with significant progress in H1 2023

Collaboration of Xlife Sciences and the Department of Health – Abu Dhabi to drive global innovations in the life sciences sector

Media Release Zurich, June 20, 2023   Xlife Sciences: shareholders approved all motions at today’s AGM 2023

Xlife Sciences publishes agenda for Annual General Meeting 2023

Xlife Sciences: Valuation Report 2022 confirms and emphasizes long-term portfolio potential

Xlife Sciences publishes 2022 results and 2023 outlook

saniva diagnostics receives approval from the US FDA for its medical product NeuroMex

Stifel initiates research coverage of Xlife Sciences

Xlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent OfficeTitle

Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS)

Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies

alytas therapeutics collaborates with spin-off from the German Diabetes Center

Xlife Sciences initiates a review of strategic options